INFORMATION FOR
News
In Memoriam for David S. Fischer, MD, community oncologist with a decades-long association with Yale New Haven Hospital and the Yale Cancer Center
According to the Centers for Disease Control and Prevention, cancer is a leading cause of death in the United States. Unfortunately for American men, prostate cancer remains one of the deadliest cancers. The Veterans Aging Cohort Study (VACS) Consortium sought to give physicians and other medical professionals guidance on how to determine treatment in patients with prostate cancer.
Using a new computational method based on a causal inference framework, CINEMA-OT, the Yale team studied how individual immune cells react to combinations of cytokines, or small proteins released by cells that regulate inflammation. They discovered that certain cytokines have a synergistic effect, inducing unique gene activation programs compared to their individual effects. This cryptography of cytokine signals acts as a language, instructing immune cells.
Uncovering the mechanisms behind a mischaracterized drug could shed light on its poor performance in clinical trials, research suggests.
Centerpoint article on research and collaboration
The 2nd Annual Yale Urology Bulldog Debates featured a new resident surgical skills event, an inaugural alumni medal, special guest keynotes, and Yale faculty presentations and rebuttals - on everything from semen analysis and pediatric pyeloplasty to reconstruction techniques and renal mass treatments.
Yale Ob/Gyn Faculty were invited to speak at the Preserving Hope: Fertility Care For Patients With Cancer and Hematological Disorders conference.
Congratulations to the following Yale Department of Internal Medicine faculty members, who were recently promoted, appointed, or reappointed.
Unplanned hospitalizations for patients with advanced cancer often trigger discussions about care goals and transitions to hospice. Late referrals to hospice, particularly near the end of life, have been associated with reduced quality of life and increased healthcare costs. A new research study published in Cancer investigates the impact of oncology hospitalists on the timing of hospice transitions for patients with advanced cancers.
Congratulations to the following Yale Department of Internal Medicine faculty members, who were recently promoted, appointed, or reappointed:
The Yale Department of Internal Medicine is pleased to highlight the following promotions to professor of medicine.
Announcing the 2024 Medical Oncology-Hematology Fellows!
Merkel cell carcinoma is a rare, aggressive skin cancer, developing in fewer than 2,000 patients in the United States annually. The disease typically presents as a red-violet, painless bump on sun-exposed skin, and definitive treatment requires surgery to remove the cancer. Because recurrence is common, patients are routinely followed for three years after excision.
Yale Urology brought together members of its expert faculty and renowned guest speakers for a carefully crafted CME curriculum at the Yale Club in New York City. The "bulldog debate" format included five distinct sections, focusing on the latest in endourology, FPMRS, prostate cancer, reproductive and sexual medicine, and bladder cancer.
As a part of our “Meet Yale Internal Medicine” series, today’s feature is on Jacquelyne Gaddy, MD, Assistant Professor of Medicine (Medical Oncology).
In the new report, there are updates from our clinical programs, research endeavors, our work on diversity, equity, and inclusion, and educational programs. Our faculty members were honored for their educational excellence. Research initiatives at Yale received applause on the national and international stages. This book highlights all that we have accomplished together this past year…
Using bioadhesive nanoparticles from the laboratory of Dr. W. Mark Saltzman, Dr. Michael Girardi and his team collaborated with Dr. Saltzman and loaded them with a one-two punch of chemotherapy plus immunotherapy to study its impact in skin cancer. The results may have significant impact for how skin cancer tumors are treated.